Avalo Therapeutics (NASDAQ:AVTX) Given Buy Rating at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $58.00 price objective on the stock. BTIG Research’s price objective would suggest a potential upside of 304.75% from the company’s previous close.

A number of other analysts have also commented on the company. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Wolfe Research assumed coverage on Avalo Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price target for the company. Bank of America assumed coverage on Avalo Therapeutics in a research note on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX opened at $14.33 on Tuesday. The firm has a market cap of $753.33 million, a PE ratio of -2.62 and a beta of 0.83. Avalo Therapeutics has a fifty-two week low of $4.46 and a fifty-two week high of $24.27. The business has a 50 day moving average price of $15.55 and a 200-day moving average price of $16.14.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. Research analysts predict that Avalo Therapeutics will post -2.58 EPS for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at approximately $116,239.20. This trade represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $65,232.22. This represents a 52.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 112,586 shares of company stock valued at $2,089,651. 4.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. Caligan Partners LP purchased a new position in Avalo Therapeutics during the third quarter valued at $10,592,000. Balyasny Asset Management L.P. bought a new position in shares of Avalo Therapeutics during the third quarter valued at $10,390,000. Vanguard Group Inc. increased its holdings in shares of Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after acquiring an additional 525,696 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after acquiring an additional 522,548 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its holdings in shares of Avalo Therapeutics by 806.0% during the first quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after acquiring an additional 510,540 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.